Abstract
Background: Weight gain and other anthropometric measures on the risk of ovarian cancer for women with BRCA mutations are not known. We conducted a prospective analysis of weight change since age 18, height, body mass index (BMI) at age 18, and current BMI and the risk of developing ovarian cancer among BRCA1 and BRCA2 mutation carriers. Methods: In this prospective cohort study, height, weight, and weight at age 18 were collected at study enrollment. Weight was updated biennially. Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% confidence intervals (CI) for ovarian cancer. Results: This study followed 4,340 women prospectively. There were 121 incident cases of ovarian cancer. Weight gain of more than 20 kg since age 18 was associated with a 2-fold increased risk of ovarian cancer, compared with women who maintained a stable weight (HR, 2.00; 95% CI, 1.13-3.54; P ¼ 0.02). Current BMI of 26.5 kg/m2 or greater was associated with an increased risk of ovarian cancer in BRCA1 mutation carriers, compared with those with a BMI less than 20.8 kg/m2 (Q4 vs. Q1 HR, 2.13; 95% CI, 1.04-4.36; P ¼ 0.04). There were no significant associations between height or BMI at age 18 and risk of ovarian cancer. Conclusions: Adult weight gain is a risk factor for ovarian cancer in women with a BRCA1 or BRCA2 mutation. Impact: These findings emphasize the importance of maintaining a healthy body weight throughout adulthood in women at high risk for ovarian cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2038-2043 |
| Number of pages | 6 |
| Journal | Cancer Epidemiology Biomarkers and Prevention |
| Volume | 30 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2021 |
Funding
This work was supported by the Canadian Institutes of Health Research (FDN 154275); Canadian Cancer Society Research Institute (703058); and the Peter Gilgan Center for Women's Cancers at Women's College Hospital in partnership with the Canadian Cancer Society. Joanne Kotsopoulos is a recipient of a Tier II Canada Research Chair. Steven A. Narod is the recipient of a Tier I Canada Research Chair. Our sincere gratitude for the valuable contributions of the women who participated in this study, without whom this research would not be possible. L. Senter reports other from AstraZeneca outside the submitted work. W.D. Foulkes reports grants from AstraZeneca outside the submitted work. C.F. Singer reports grants and personal fees from Novartis; grants, personal fees, and non-financial support from Roche and AstraZeneca; and grants and non-financial support from Amgen during the conduct of the study. O.I. Olopade reports other from CancerIQ, Tempus, and 54gene outside the submitted work. J.N. Weitzel reports personal fees from AstraZeneca outside the submitted work. No disclosures were reported by the other authors. This work was supported by the Canadian Institutes of Health Research (FDN 154275); Canadian Cancer Society Research Institute (703058); and the Peter Gilgan Center for Women’s Cancers at Women’s College Hospital in partnership with the Canadian Cancer Society. Joanne Kotsopoulos is a recipient of a Tier II Canada Research Chair. Steven A. Narod is the recipient of a Tier I Canada Research Chair. Our sincere gratitude for the valuable contributions of the women who participated in this study, without whom this research would not be possible. We would like to acknowledge the other members of the Hereditary Ovarian Cancer Clinical Study Group: Jacek Gronwald, Cezary Cybulski, Tuya Pal, Georgia Wiesner, Barry Rosen, Jeanna McCuaig, Raymond Kim, Rochelle Demsky, Kevin Sweet, Dana Zakalik, Marie Wood, Wendy McKinnon, Christine Elser, Georgia Wiesner, Eitan Friedman, Wendy
ASJC Scopus subject areas
- General Medicine
